Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NextCell Pharma AB ("NextCell" or "the Company") announces that its CSO, Lindsay Davies, has been asked to lead the inaugural International Society of Cell and Gene Therapy (ISCT) industry committee for Europe and has been nominated as Vice President Elect in the 2025 ISCT elections.
The ISCT is a global society of clinicians, regulators, researchers, technologists, and industry partners focussed on translating cell and gene technologies into therapies that can be used to treat conditions with unmet clinical need. The society is the world leading society focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics with over 4000 subject matter experts across the globe active members.
"The nomination to such a prominent role in the society and associated Board of Director membership that is extended to VPs demonstrates Lindsay's distinguished position in the CGT community. We are proud to support her involvement in the society and wider contributions to Europe," says Mathias Svahn, CEO.
NextCell Pharma is an active member of the global industry committee, collaboratively working with industry and academia to increase awareness of key issues in the field of cell and gene therapy (CGT). Lindsay Davies, as a member of this committee and its working groups, has published two peer-reviewed articles of the importance of particulates in CGTs in the society's journal, Cytotherapy1,2.
ISCT has announced that it will form a new committee specifically addressing the European industry community working with CGT development and has invited Dr Davies to spearhead this initiative as Chair. She will be responsible for developing the charter for the work that the committee will conduct and establish the founding members.
"I have been a member of the ISCT for over 12 years and enjoy being an active member, contributing to the global industry group, mentoring early stage professionals and acting as the European Secretary since 2023," says Dr Davies. "It is an honour to now be recognised as the inaugural Chair for the newly formed European Industry Committee. I have worked with Head Office at ISCT to develop a case for such a committee, representing European CGT interests, focussed on the unique considerations developers in academia and industry face when translating a cell or gene therapy inside of Europe. This is distinctly different to experiences inside other jurisdictions like North America, and we needed a committee to address this."
In addition to this recognition of Dr Davies' contribution and standing in the European CGT community, she has also been nominated for the role of Vice President Elect at this year's ISCT elections.
The election is ongoing, with the opportunity to vote closing on 24th March. The final results will be shared in early April.
References
- Particulates are everywhere, but are they harmful in cell and gene therapies?
Molina SA, Davies SJ, Sethi D, Oh S, Durand N, Scott M, Davies LC, Wormuth K, Clarke D. Cytotherapy. 2022 Dec;24(12):1195-1200. doi: 10.1016/j.jcyt.2022.07.014
- Particulates in CGT guidance survey results - an ISCT process development & manufacturing committee perspective on cell and gene therapy industry knowledge awareness.
Durand N, Davies L, Davies S, McGowan D, Clarke D, Oh S, Sethi D, Werner S, Molina SA; Manufacturing Materials Safety & Technology Working Group (formerly the Particulate Working Group) within the ISCT Process Development & Manufacturing Committee. Cytotherapy. 2025 Mar;27(3):287-294. doi: 10.1016/j.jcyt.2024.10.004